Steven Hamilton, PhD, MD.
Psychiatrist, The Permanente Medical Group, Kaiser-Permanente San Francisco Medical Center, Clinical faculty, Department of Psychiatry, University of California, San Francisco.
Dr. Hamilton has disclosed that he is an unpaid scientific advisor to 23andMe, which offers a commercial genome test. Dr. Balt has reviewed this interview and found no evidence of bias in this educational activity.Dr. Lanocha has disclosed that he received a $6,000 payment in the last year from the speakers’ bureau of Neuronetics, the makers of the NeuroStar TMS system. Dr. Carlat has reviewed this interview to ensure the absence of commercial bias, either in favor of any particular TMS product, or in favor of TMS over other treatment options. In a future issue of TCPR, we will review the most recent efficacy literature and will compare the pros and cons of specific TMS devices.
Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.webp?t=1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
RSS
